Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California. Show more
One Letterman Drive, San Francisco, CA, 94129, United States
Market Cap
2.253B
52 Wk Range
$24.31 - $32.00
Previous Close
$25.02
Open
$25.41
Volume
829,354
Day Range
$23.42 - $25.41
Enterprise Value
2.134B
Cash
122.8M
Avg Qtr Burn
-16.95M
Insider Ownership
58.16%
Institutional Own.
19.14%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
BHB-1893 Details Symptomatic nHCM without significant LVOT obstruction | Phase 3 Initiation | |
BHB-1893 Details Adults with symptomatic oHCM, including NYHA Class II–III patients | Phase 3 Initiation |
